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Abnormal tissue levels of certain trace elements such as zinc (Zn) were reported in various types of cancer. Little is known about
the role of Zn in osteosarcoma. Using confocal synchrotron radiation micro X-ray fluorescence analysis, we characterized the spa-
tial distribution of Zn in high-grade sclerosing osteosarcoma of nine patients (fourwomen/fivemen; seven knee/one humerus/one
femur) following chemotherapy and wide surgical resection. Levels were compared with adjacent normal tissue. Quantitative
backscattered electron imaging as well as histological examinations was also performed. On average, the ratio of medians of
Zn count rates (normalized to calcium) in mineralized tumor tissue was about six times higher than in normal tissue. There was
no difference in Zn levels between tumor fraction areas with a low fraction and a high fraction of mineralized tissue, which were
clearly depicted using quantitative backscattered electron imaging. Moreover, we found no correlation between the Zn values
and the type of tumor regression according to the Salzer-Kuntschik grading. The underlying mechanism of Zn accumulation re-
mains unclear. Given the emerging data on the role of trace elements in other types of cancer, our novel results warrant further
studies on the role of trace elements in bone cancer. Copyright © 2016 The Authors. X-Ray Spectrometry published by JohnWiley &
Sons Ltd.
Introduction
Osteosarcoma is themost common primary malignant bone tumor
with a peak incidence in childhood and adolescence frequently
occurring at sites of rapid bone growth[1] with a second smaller in-
cidence peak in the elderly. While the exact cell of origin for this
cancer remains to be ill-defined, osteosarcoma cells produce
osteoid and tumor matrix that can mineralize. Due to the use of
neoadjuvant chemotherapy, long-term survival of patients with os-
teosarcoma has improved from 10% to 20% to nearly 80% within
the last 25 years.[2,3] However, these rates have not improved in
the last 15 years.[2,3] Therefore, it is essential to obtain more insight
into the fundamental biology of osteosarcoma that may lead to
new treatment.[4] Trace elements have recently become a field of
interest in various physiological as well as disease processes and
especially cancer.[5–7] It was found that trace element levels differ
between normal and cancerous tissue.[7–10] Moreover, novel
approaches using trace elements to treat cancer have recently
emerged.[11]
Zinc (Zn) is an essential trace element implicated in several
biological processes, and various studies reported significant
changes in the levels of Zn in different cancer types.[8–10,12] Zn
is also an important trace element for bone metabolism.[13] Zn
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levels are known to affect the proliferation rate of osteoblasts.[14]
The Zn concentration is higher in bone than in most of the other
tissues.[13] Technical advances in recent times allow the spatial
characterization of trace elements in tissues. Confocal synchrotron
radiation micro X-ray fluorescence (SR-μXRF) having a well-
defined depth information (about 20μm) has proven to be an ef-
fective imaging method for qualitative and semiquantitative anal-
ysis of spatial distribution of trace elements in different
materials.[15] We have successfully used this technique to charac-
terize spatial distribution of various trace elements in cartilage
and bone samples.[16–18] However, little is known about Zn levels
in osteosarcoma. The aims of this study were to investigate the
Zn content as well as its spatial distribution in human mineralized
osteosarcoma tissue and compare it to adjacent normal bone
using both confocal SR-μXRF and quantitative backscattered elec-
tron imaging (qBEI) acquiring the signals only from near surface
(about 1-μm-depth resolution).
Materials and methods
Patients
Nine patients (four women/five men) with a highly malignant G3
osteosarcoma underwent wide resection of the tumor and implan-
tation of a tumor prosthesis following neoadjuvant chemotherapy
according to standardized protocols.[19] Eight patients were
between 10 and 18 years old, and one patient was 66 years old
(Table 1). Seven samples were from the knee joint, and one was
from the proximal femur and one from the proximal humerus.
Grades of regression were classified histologically according to
Salzer-Kuntschik et al.[20] Details are summarized in Table 1. The
studywas approved by the ethics committee of theMedical Univer-
sity of Vienna, Austria, and was performed in accordance with the
Helsinki Declaration.
Sample preparation
All bone/tumor tissue samples were dehydrated and fixed in a gra-
dient of ethanol concentration (50% to 100%) and embedded in
polymethylmethacrylat. The sample blocks were trimmed by a
low-speed diamond saw (Buehler Isomet, Lake Pluff, USA), and
3-μm-thick tissue sections were cut by a hard microtome (LEICA
SM2500; LeicaMicrosystems GmbH,Wetzlar, Germany) for histolog-
ical examinations (Fig. 1). Modified trichrome Goldners and Giemsa
staining was performed in representative samples. Consecutively,
the blocks were ground with sandpaper with decreasing grit size
and finally polished by silk cloths loaded with diamond grains
(3μm and 1μm) using a precision polishing device (PM5; Logitech
Ltd., Glasgow, UK). A flat surface of the sectioned tissue area is cru-
cial for qBEI and SR-μXRF measurements. The bone tissues in the
sample blocks obtained by this procedure were of varying thick-
ness in the 2- to 3-mm range. Afterward, the sample blocks were
coated with a thin carbon layer by vacuum evaporation (Agar
SEM Carbone coater; Agar Scientific Limited, Essex, UK) to avoid
electrical charging effects during backscattered electron imaging.
A more detailed description of the sample preparation can be
found in previous publications.[21,22]
Quantitative backscattered electron imaging
Quantitative backscattered electron imaging gives a signal propor-
tional to the average atomic number of the target material. For
bone calcium (Ca) – the major bone constituent with the highest
atomic number (Z=20) – prevails the signal that allows one to de-
termine the degree of tissue matrix mineralization (Ca content) at
each pixel area of the imaged tissue section. In the qBEI images,
bright areas describe higher mineralized matrix and dark areas
lower mineralized matrix. A digital scanning electron microscope
(DSM 962; Zeiss, Oberkochen, Germany) equipped with four quad-
rant semiconductor backscattered electron detector was used. The
scanning electron microscope was operated at 20 keV beam en-
ergy, and regions of interest (ROIs) were imaged with 200× nominal
magnification (pixel resolution 1μm). The information depth of the
qBEI depends on themineralization and is in the range of 1–1.5μm.
An example of ROIs, in which consecutively Zn content
measurements/mapping were performed, is shown in Fig. 1 as well
as histological images of tissue sample sections from the same
patient and a radiography of the patient’s knee joint. The qBEI mea-
surements for one sample (P1) were previously presented in detail
as a case study.[23] A significantly higher degree of mineralization
(Ca content) was reported in the tumor bone tissue compared with
the surrounding healthy bonematrix. More information about qBEI
can be found elsewhere.[21,22]
Confocal synchrotron radiation micro X-ray fluorescence
analysis
Confocal SR-μXRF has proven to be a powerful tool for qualitative
and semiquantitative analysis of spatial distribution of trace ele-
ments in bone samples.[16–18,24] This method takes advantage of
various characteristics of synchrotron radiation such as high photon
flux, linear polarization, collimation and the easily tunable primary
photon energy that enables to detect absolute amounts in the
femtogram range (for medium Z elements). Confocal SR-μXRF uses
X-ray optics (often polycapillary lenses) on the beam side and in
front of the detector to define a detection volume from which the
fluorescence radiation is detected, which allows to acquire informa-
tion from the ROI voxel by voxel. Furthermore, the confocal setup
eliminates fluorescence radiation (of higher energies in particular
of high Z elements) from deeper layers and therefore improves
the overall spatial resolution. Further details on confocal SR-μXRF
can be found elsewhere.[15,25]
Synchrotron radiation μXRFmeasurements were performedwith
a confocal setup at the FLUO beamline at ANKA (KIT, Karlsruhe,
Germany)[25] duringmultiple beamtimes. For this setup, aW/Si dou-
ble multilayer was used for monochromatization, keeping the
Table 1. List of analyzed samples
Patient n Tissue Age (years) Regression grade
P1 5 Prox. tibia 11 4
P2 5 Prox. tibia 12 2
P3 5 Prox. femur 66 2
P4 6 Dist. femur 18 2
P5 4 Dist. femur 18 2
P6 3 Dist. femur 17 2
P7 3 Prox. tibia 14 3
P8 6 Prox. fibula 10 3
P9 4 Prox. humerus 10 3
Prox., proximal; Dist., distal.
n is the number of the measured areas; regression grades refer to the
histological grade of regression as defined by Salzer-Kuntschik et al.[20]
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beam exit position constant for various energies. The excitation en-
ergy was chosen at 17 keV. As focusing optics, two polycapillary half
lenses were used. The fluorescence radiation was detected with a
50-mm2 silicon drift detector (Vortex). The detection volume for
the setup was estimated by scanning 0.1-μm-thick gold (Au) micro-
structures. As the size of the detection volume is energy depen-
dent, the step sizes were chosen to be slightly smaller than the
detection volume for Au-Lα (9.711 keV). The step sizes varied be-
tween 10×10μm2 and 10×17μm2 for the different beamtimes.
A depth resolution at 9.71 keV (Au-Lα) was about 20μm, meaning
that only signals from this layer were detected. Prior to the area
scan of a bone region, depth scans were performed at a few se-
lected points of the ROI. The depth of the highest Ca signal was
chosen for the complete area scan. The voxel dimensions achieved
for that energy were therefore 10×10×20μm3, respectively,
10 ×17×20μm3. Thus, we measured all elements within a layer
only and avoided signals having a larger information depth. The
acquisition time of the μXRF signal per voxel was chosen by the sig-
nal to noise ratio of test measurements. For most samples, 2 s was
sufficient. All spectra were dead time corrected. A typical spectrum
obtained in a voxel of a mineralized tissue is shown in Fig. 2.
Data evaluation
The spectra acquired in each voxel were processed using AXIL
software.[26] Net counts per Ca and Znwere converted to text maps
(further referred to as elemental maps).
Custom-made software was written in python (v.3.4)[27] for fur-
ther data processing using the following modules: numpy,[28]
scipy[29] and matplotlib.[30] The following evaluation steps were
performed:
Figure 2. Typical synchrotron radiation micro X-ray fluorescence spectrum
as obtained from a voxel inside a mineralized bone matrix. Data acquisition
time was 3 s.
Figure 1. Radiograph (a) of a knee joint with a sclerosing osteosarcoma. The red box indicates the region examined by quantitative backscattered electron
imaging. Backscattered electron image (b) showing an overview of a tissue sample. Two regions of interest (ROIs) selected for consecutive Zn synchrotron
radiation micro X-ray fluorescence analysis are indicated. ROI 1 contains healthy bone tissue together with a tumor tissue area, which is mineralized to an
extremely high percentage. Further, the tissue matrix itself is mineralized to a much higher degree than normal bone. ROI 2 contains a tumor tissue area,
which is mineralized to a much lower percentage than in ROI 1. Representative histological images of tissue sample sections from the same patient: (c)
healthy trabecular bone area with intact bone marrow compartment; modified trichrome Goldners staining: green mineralized trabecular bone feature
(★), brownish bone marrow cells (■) and white fat cells (▲). (d) Tumor-affected bone tissue: normal trabecular bone (★), non-mineralized (•) and
mineralized (♦) tumor matrix, (e) region of mineralized (♦) and non-mineralized (•) tumor matrix (Giemsa staining).
M. Rauwolf et al.
wileyonlinelibrary.com/journal/xrs Copyright © 2016 The Authors. X-Ray Spectrometry
published by John Wiley & Sons Ltd.
X-Ray Spectrom. 2017, 46, 56–62
5
8
1 All elemental maps were normalized to 100 mA ring current and
counts per second (cps).
2 No Zn was detected in the non-mineralized tumor tissue as well
as bonemarrow. Therefore, we focused our analysis solely on the
mineralized tissue areas.We differentiated between tumor tissue
and adjacent normal bone, which can be easily distinguished
based on the backscattered electron images. As there was no
Zn, a threshold was introduced in the Ca maps to clearly seg-
ment between mineralized tissue areas and soft tissue areas
and/or embedding medium. This was performed in an adaptive
manner using Eqn (1) for each ROI, because of variations in tissue
characteristics and experimental conditions on the synchrotron
between the different measurements sessions. A value of 0.5
for level (a factor with which the difference between maximum
and minimum Ca count rate is multiplied) in Eqn (1) turned out
to be a suitable level to evaluate the tissue samples. By this
way, partially filled volume effects occurring at the edges be-
tween the mineralized and adjacent nonmineralized regions
were minimized. Thus, regions around small voids could be ex-
cluded from Zn evaluation.
TBone ¼ Camin þ level Camax  Caminð Þ (1)
TBone is the threshold value for themineralized tissue. All voxels with
a lower Ca count rate than TBone are excluded in the Zn map analy-
sis. Camin represents the minimal Ca count rate of a sample area
(ROI). Camax stands for the maximal Ca count rate in the same ROI.
The variable level can be assigned any value between 0 and 1.
3 Areas of all samples were classified as tumorous or healthy by
inspecting the corresponding qBEI images. For sample areas
containing both healthy and diseased tissue such as shown in
Fig. 3(a) to (c), masks were created as binary images in ImageJ
(v1.48o, National Institutes of Health, USA),[31] which then were
used by the software to allocate the various pixels of the sample
area to healthy bone and to tumor tissue.
4 Compared with the qBEIs, the elemental maps have a much
lower depth resolution. As we only know the surface structure
(seen in microscope pictures and qBEI images) of the samples,
we corrected count rates for Zn to the Ca signal (Eqn (2)). The rel-
ative Zn content of a voxel (Zn fraction) was defined as the frac-
tion of the Zn count rate from the total count rates of Ca
(CountsCa) and Zn (CountsZn) together. Otherwise, areas with
holes underneath the sample surface might have been evalu-
ated as areas with low Zn content (CountsZn), although related
to the available bone tissue [represented by the Ca count rate
(CountsCa)], the Zn content might have actually been higher.
The calculation of the Zn fraction was chosen over the Zn/Ca-
ratio because it will limit the result to a value between 0 and 1,
while the ratio could also result in values bigger than 1.
Zn fraction ¼ CountsZn= CountsCa þ CountsZnð Þ (2)
5 Mean, standard deviation, 5-percentile, 25-percentile,
50-percentile (= median), 75-percentile and 95-percentile of
the Zn fraction data were determined for each sample area
(ROI) as well as for each sample.
6 Frequency distributions of voxels with certain Zn fraction values
were plotted (Zn histograms).
7 Boxplots showing the median (black horizontal line), mean
(black square), a colored box starting at the 25th percentile
and ending at the 75th percentile (containing 50% of the data)
and whiskers reaching from the 5th to 95th percentile (and
therefore representing a 90% confidence interval) were created.
8 Moreover, we investigated if the Zn count rate differs with
respect to the calcium content in highly mineralized areas versus
lowly mineralized areas.
Statistical analysis
Statistical comparison was performed between the groups of me-
dian Zn fraction of healthy bone tissue versus tumor tissue. Because
healthy and tumor tissue was measured from the same sample, a
paired test was appropriate. Further, because of the small sample
size, it would be unreasonable to assume normal distribution of
the measured data; thus, a Wilcoxon signed-rank test was per-
formed using tabulated critical values.[32] We correlated the Zn
Figure 3. Example of confocal synchrotron radiation micro X-ray fluorescence (SR-μXRF) analysis in ROI 1 (a–c) and ROI 2 (d–f) of a mineralized tumor tissue
from patient P1: qBEIs are reflecting the mineral content where Ca and Znmapping was performed (a and d). Ca maps (b and e) are given in units counts per
second; Znmaps (c and f) are given as fraction of Zn count rates per total (Ca + Zn) count rates. SR-μXRF, synchrotron radiationmicro X-ray fluorescence; ROI,
region of interest; qBEIs, quantitative backscattered electron imagings.
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fractions of each tumor to the Salzer-Kuntschik regression grade in
order to see if there is a relationship between the Zn fractions and
chemotherapy response.
Results
As an example, two ROIs within the sample from patient P1 are
shown in Fig. 1. ROIs with different tumor characteristics were
selected, and resulting Ca count rates and Zn fraction maps with
corresponding histograms were determined. The ROI 1 contains
both tumor tissue and healthy bone: The classification of the re-
gions is given in the qBEI image (Fig. 3a); one can see that the min-
eralization and accordingly also the Ca content are distinctly lower
in the healthy part than in the tumor area (Fig. 3b). In parallel, the
Zn fraction was tremendously increased in tumor area compared
with the healthy bone area (Fig. 3c). The qBEI, Ca map and Zn frac-
tions map of ROI 2 (Fig. 3d–f) show an area containing exclusively
tumor tissue, which is mineralized to a much lower percentage
(meaning that there are less pixels containing mineralized tissue)
than ROI 1.
The histogram of Zn fractions of all five ROIs of P1 is shown at
once in Fig. 4. Two separated peaks (light gray bars healthy and
dark gray bars tumorous region) are visible. Boxplots for the same
data set are also shown in Fig. 4 (underneath the histogram). The
90% confidence intervals of the healthy and the tumorous areas
are distinctly separated. Only a few outliers of those two distribu-
tions overlap. Zn fractions with their means and standard devia-
tions over the healthy and the tumor regions of the nine patients
are shown in Fig. 5. As one can see, the Zn mean values for the tu-
morous regions of a patient are always higher than those for the
healthy regions. Figure 6 compares the Zn fraction distribution for
healthy and tumorous tissue areas of all patients. The histograms
were normalized so that the data of each patient contribute equally
and independently of the number of points measured per patient.
As one can see, the Zn fraction distribution of the healthy and tu-
morous areas are clearly separated, and Zn content in the tumorous
areas is a lot higher in the osteosarcoma tissue compared with the
surrounding healthy tissue.
TheWilcoxon signed-rank test showed that themedian of the tu-
morous areas of a patient is significantly higher (p< 0.005) than the
median of the healthy areas of the same patient.
The average x¯ð Þ of the median ratios (tumorous Zn fractions me-
dian divided by healthy Zn fractions median) of all nine patients
and its standard deviation σx¯ð Þcan be reported as 6.05 3.02. While
the weighted mean for the nine Zn fraction ratios (mean of tumor-
ous Zn fractions divided by the mean of healthy Zn fractions) and
their standard deviations results to x¯  σx¯ = 3.67 0.12. As one
can see from both the weighted average and average of the me-
dian ratios, the Zn count rate in the tumorous areas of the samples
is at least about four times higher than that in the healthy areas of
the samples.
Furthermore, we did not find a significant difference in Zn/(Zn
+Ca) ratio in lowly mineralized tumor areas versus highly mineral-
ized tumor areas, indicating this ratio is relatively unchanged.
Both mean and median of Zn fractions were compared with the
histological grade of regression for each patient. No correlation be-
tween Zn fraction values and grades of regression were found, indi-
cating that Zn levels did not correlate with the response to
chemotherapy.
Discussion
Synchrotron radiation-induced confocal μXRF was used to evaluate
trace elements in human osteosarcoma tissue. The study revealed
tremendously higher Zn fractions in mineralized osteosarcoma re-
gions compared with the healthy bone areas of the same patient.
On average, the Zn fraction median for tumorous bone areas was
six times higher than that for healthy bone areas. In our samples,
we found regions with varying fractions ofmineralized tumor tissue
areas. Interestingly, we did not find a significant difference in
CountsZn/(CountsCa+CountsZn) ratio between tumor areas with a
low or high fraction of mineralized tissue, indicating that this ratio
is relatively constant.
Other groups have observed changes in Zn levels in connection
with various cancer types. For instance, Christudoss et al. reported
decreased levels of mean tissue Zn (83% and 61%) and plasma
Zn (27% and 18%) compared with controls in benign prostatic hy-
perplasia and prostate carcinoma.[9] Zn concentration was also
found to be significantly decreased in serum for liver cancer
Figure 4. Histogram and boxplots for the Zn fractions over all the healthy
(light gray) and tumorous (dark gray) areas of P1.
Figure 5. Comparison of means and standard deviations of Zn fractions
between healthy bone (light gray circles) and mineralized tumor (dark
gray triangles) matrix for each patient.
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compared with in normal serum.[10] The same study also reported
lower Zn tissue concentrations in cancerous and non-cancerous
livers of hepatoma patients compared with those in normal livers.
A meta-analysis of tissue and serum Zn in epithelial malignancies[5]
confirmed the decrease of serum Zn levels in lung, breast, liver,
stomach and prostate cancers and Zn tissue levels in prostatic, liver,
lung and thyroid cancer. A clear increase of Zn was only found in
cancerous breast tissue. Moreover, the results of Al-Ebraheem
et al.[12] imply an interrelation between the sites of cancer cell clus-
ters and higher concentrations of Zn, Fe, Cu and Ca in breast tissue.
In our study, we did not see a significant correlation between the
Zn fraction values and the response to chemotherapy.
The mechanisms underlying the changes in the Zn concen-
tration between healthy and tumorous mineralized tissue can
only be speculated about at this time. As Zn stimulates bone
formation,[33,34] higher Zn fractions in mineralized tumor tis-
sue compared with healthy mineralized tissue seem perspicu-
ous. Zn is an essential trace element implicated in several
biological processes including bone metabolism.[13] Zn ions
are used by many proteins to stabilize their structure. For ex-
ample, Zn finger proteins are among the most abundant pro-
teins in eukaryotic genomes. Many of them are involved in
transcriptional regulation.[35] Moreover, Zn is also a cofactor
of several enzymes in bone such as the tissue nonspecific al-
kaline phosphatase, which plays an important role in bone
matrix mineralization.[36,37]
In a recent study, we found homogenous Zn concentration
within bone structural units, while increased Zn concentrations
were observed in the cement lines separating the differently aged
bone structural units.[18] Interestingly, the Zn concentration was
not correlated with the degree of bone matrix mineralization in
the different bone structural units, which suggests that Ca is not a
significant factor for explaining the Zn concentration in bone and
that Zn is therefore likely under homeostatic control.[38] Zn in the
mineralized bone matrix is bond to hydroxyapatite very likely dur-
ing the early phase of the mineralization process.[39] It seems that
Zn is not just incorporated by ion exchange, but by substitution
of vacancy defects of Ca2+.[40]
However, it is noteworthy that no Zn was found in the surround-
ing soft tumor tissue. As it cannot be entirely ruled out that Zn in
soft tissue is lost during sample preparation, cryosections should
be analyzed in future studies.
Furthermore, it should be mentioned that our samples were
taken after chemotherapy. While it is known that chemotherapy
of osteosarcomas has limited effect on the tumor mineralization,[41]
we do not know if the chemotherapy-induced necrosis has any
influence on Zn fractions.
Ambroszkiewicz et al. investigated serum bone turnover
markers,[42] such as bone alkaline phosphatase (BALP), which
contains Zn as coenzyme,[43] in children and adolescents with
osteosarcoma. Among other things, their findings suggest that
BALP levels decrease (from levels similar to healthy patients)
during preoperative chemotherapy for all patients and
significantly lower values for patients with good prognosis
compared with patients with poor prognosis during postoper-
ative chemotherapy and after therapy were found.[42] Another
study[44] was reported to have found no significantly different
serum Zn values in patients with osteosarcoma compared
with age-matched and sex-matched controls. Future studies
combining measurements of Zn distribution in mineralized
healthy and tumorous tissue of osteosarcoma patients as well
as of BALP values and serum Zn levels at different stages of
the treatment could provide new insights into the role of Zn
in osteosarcoma.
Due to the complexity of bone structure, there is no acceptable
referencematerial for calibration of the μXRF setup available, which
would allow quantifying the absolute trace element concentrations
corresponding to the measured count rates. While higher count
rates equate higher concentrations, no absolute values (wt%), but
only relative values (Zn fractions in the volume), can be given. As
the osteosarcoma tissues are not easy to acquire the sample size
was rather small (n=9). Heterogeneity of the samples exists
Figure 6. Zn fraction distribution over all patients for healthy (top) and tumorous areas (bottom). The distributions were normalized so that each patient
contributes equally to the histogram (independently of the numbers of points measured by patient).
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concerning age, sex, localization (location of sampling), histological
specification and treatment with different types of chemotherapy.
Conclusion
Synchrotron radiation μXRF allowed us to detect Zn in mineralized
osteosarcoma tissue and normal healthy cortical and trabecular
bone. Median Zn fractions were found to be a significantly higher
in all mineralized osteosarcoma tissue areas compared with normal
adjacent bone.
However, the underlying mechanism of Zn accumulation re-
mains unclear. Given the emerging data on other types of cancer
and trace elements, future studies will need to take a closer look
at the role of trace elements and the clinical outcome of osteosar-
coma. Our findings of increased Zn fractions warrant further studies
on the role of Zn and bone cancer.
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